{"id":71212,"date":"2017-11-08T14:09:32","date_gmt":"2017-11-08T14:09:32","guid":{"rendered":"http:\/\/humanitasnet-new.local\/malattie\/mijelofibroza\/"},"modified":"2025-01-13T02:54:50","modified_gmt":"2025-01-13T02:54:50","slug":"mijelofibroza","status":"publish","type":"disease","link":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/","title":{"rendered":"Mijelofibroza"},"content":{"rendered":"<h2 id=\"definicija\">Definicija<\/h2>\n<p>Mijelofibroza je opasni poreme\u0107aj ko\u0161tane sr\u017ei. To je stanje kod koga dolazi do prekida normalne proizvodnje krvnih \u0107elija, a koje prouzrokuje stvaranje brojnih o\u017eiljaka na ko\u0161tanoj sr\u017ei \u0161to dalje rezultira anemijom, umorom, slabo\u0161\u0107u, a ponekad i uve\u0107anjem jetre i slezine. \u00a0Mijelofibroza je zaprvo jako redak oblik hroni\u010dne leukemije. Pripada grupi mijeloproliferativnih poreme\u0107aja. Neki slu\u010dajevi mijelofibroze godinama ne daju nikakve znakove i simptome bolesti. Me\u0111utim, u ve\u0107ini slu\u010dajeva, tokom vremena dolazi do pogor\u0161anja, a neki se slu\u010dajevi mogu razviti u ozbiljne oblike leukemije. Mere le\u010denja fokusiraju se na olak\u0161avanje simptoma.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"simptomi\">Simptomi<\/h2>\n<p>Mijelofibroza je bolest koja se veoma sporo razvija i \u010desto u ranim fazama, ne daje nikakve simptome. Me\u0111utim, kako se prekid u formiranju krvnih \u0107elija pove\u010dava, pojavljuju se neki od slede\u0107ih simptoma:<\/p>\n<p>Ose\u0107aj slabosti i umora<\/p>\n<p>Kratak dah<\/p>\n<p>Bledilo<\/p>\n<p>Lako krvarenje i stvaranje modrica<\/p>\n<p>Prekomerno no\u0107no znojenje<\/p>\n<p>Visoka temperatura<\/p>\n<p>Bol u kostima<\/p>\n<p>Infekcije koje se ponavljaju<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"uzroci\">Uzroci<\/h2>\n<p>\u0106elije krvi, crvena krvna zrnca i bela krvna zrnca i plo\u010dice, imaju sposobnost da se dele i umno\u017eavaju u odre\u017een broj specijalizovanih krvnih \u0107elija koje se nalaze u krvi. Kada dolazi do genetske mutacije u stem krvnim \u0107elijama, dolazi do pojave mijelofibroze. Nije poznato \u0161ta dovodi do pojave te mutacije. Kada se mutirana krvna stem \u0107elija podeli, ona prenosi tu mutaciju na novonastale \u0107elije, tako da brojdefektnih \u0107elija raste i ozbiljno ugro\u017eava proizvodnju krvi. Obi\u010dno dolazi do nedostatka crvenih krvnih zrnaca, a do vi\u0161ka belih krvnih zrnaca i plo\u010dica. Nedostatak crvenih krvnih zrnaca dove\u0161\u0107e do pojave klasi\u010dnih znakova i simptoma anemije. Ko\u0161tana sr\u017e koja bi trebalo da bude mekana i sun\u0111erasta, postaje tkivo sa o\u017eiljcima. Kao mutirani gen koji se javlja u ve\u0107ini slu\u010dajeva mijelofibroze ponekad se navodi JAK2.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"faktori-rizika\">Faktori rizika<\/h2>\n<p>Uzrok mijelofibroze nije poznat, ali su poznati neki faktori koji pove\u0107avaju rizik do pojave bolesti. Oni su:<\/p>\n<p>Starosna dob-Ugro\u017eenije su osobe u 6. i 7. deceniji \u017eivota<\/p>\n<p>Prisustvo jo\u0161 nekog poreme\u0107aja krvi poput trombocitemije ili policitemije vera<\/p>\n<p>Izlo\u017eenost industrijskim hemikalijama poput toluena i benzena<\/p>\n<p>Izlaganje velikom stepenu radijacije<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"komplikacije\">Komplikacije<\/h2>\n<p>Neke od komplikacija koje mogu da poti\u010du do mijelofibroze su:<\/p>\n<p>Pove\u0107an pritisak u krvi koja dolazi u jetru<\/p>\n<p>Bol u stomaku i le\u0111ima<\/p>\n<p>Izrasline na drugim delovima tela<\/p>\n<p>Preterano krvarenje<\/p>\n<p>Bol u kostima i zglobovima<\/p>\n<p>Akutna leukemija<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"lecenje\">Le\u010denje<\/h2>\n<p>Ukoliko simptomi i vidljivi znaci anemije nisu prisutni, onda osobi sa mijelofibrozom verovatno nije potrebno le\u010denje. Me\u0111utim, lekar bi trebalo da prati stanje pacijenta kako bi uo\u010dio bilo kakve promene, simptome i napredovanje bolesti.<\/p>\n<p>Postoje neke nau\u010dne studije koje rade na otkri\u0107u leka kojim \u0107e se targetirati mutacija gena JAK2 koji se smatra odgovornim za nastanak mijelofibroze.<\/p>\n<p>Ukoliko mijelofibroza dovodi do nastanka anemije, trebalo bi uzeti u obzir neke od slede\u0107ih na\u010dina le\u010denja:<\/p>\n<p>Transfuziju krvi<\/p>\n<p>Androgenu terapiju<\/p>\n<p>Talidomide i sli\u010dne lekove<\/p>\n<p>&nbsp;<\/p>\n<p>Kada do komplikacija dolazi zbog uve\u010dane slezine, lekar mo\u017ee preporu\u010diti neke od ovih na\u010dina le\u010denja:<\/p>\n<p>Splinektomija-hirur\u0161ko uklanjanje slezine<\/p>\n<p>Hemoterapija<\/p>\n<p>Terapija zra\u010denjem<\/p>\n<p>&nbsp;<\/p>\n<p>Kao jo\u0161 jedna opcija le\u010denja izdvaja se i transplantacija stem \u0107elija od odgovaraju\u0107eg donora. To je zapravo jedini mogu\u0107i na\u010din koji ima u sebi potencijal da izle\u010di mijelofibrozu, ali nosi rizik od nus pojava koje mogu biti fatalne.<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-71212","disease","type-disease","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mijelofibroza - Humanitas.net<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"sr_RS\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mijelofibroza - Humanitas.net\" \/>\n<meta property=\"og:description\" content=\"Definicija Mijelofibroza je opasni poreme\u0107aj ko\u0161tane sr\u017ei. To je stanje kod koga dolazi do prekida normalne proizvodnje krvnih \u0107elija, a koje prouzrokuje stvaranje brojnih o\u017eiljaka na ko\u0161tanoj sr\u017ei \u0161to dalje rezultira anemijom, umorom, slabo\u0161\u0107u, a ponekad i uve\u0107anjem jetre i slezine. \u00a0Mijelofibroza je zaprvo jako redak oblik hroni\u010dne leukemije. Pripada grupi mijeloproliferativnih poreme\u0107aja. Neki slu\u010dajevi [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/\" \/>\n<meta property=\"og:site_name\" content=\"Humanitas.net\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/HumanitasInternational\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-13T02:54:50+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@humanitasmilano\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/\",\"url\":\"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/\",\"name\":\"Mijelofibroza - Humanitas.net\",\"isPartOf\":{\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#website\"},\"datePublished\":\"2017-11-08T14:09:32+00:00\",\"dateModified\":\"2025-01-13T02:54:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/#breadcrumb\"},\"inLanguage\":\"sr-RS\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/humanitas-net.humweb.webiz.team\/sr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Malattie\",\"item\":\"https:\/\/humanitas-net.humweb.webiz.team\/malattie\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Mijelofibroza\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#website\",\"url\":\"https:\/\/humanitas-net.humweb.webiz.team\/\",\"name\":\"Humanitas.net\",\"description\":\"Humanitas Hospital\",\"publisher\":{\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/humanitas-net.humweb.webiz.team\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sr-RS\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#organization\",\"name\":\"Humanitas\",\"url\":\"https:\/\/humanitas-net.humweb.webiz.team\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sr-RS\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/humanitas-net.humweb.webiz.team\/wp-content\/uploads\/2025\/01\/new-humanitas-logo-1.svg\",\"contentUrl\":\"https:\/\/humanitas-net.humweb.webiz.team\/wp-content\/uploads\/2025\/01\/new-humanitas-logo-1.svg\",\"width\":1,\"height\":1,\"caption\":\"Humanitas\"},\"image\":{\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/HumanitasInternational\/\",\"https:\/\/x.com\/humanitasmilano\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mijelofibroza - Humanitas.net","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"sr_RS","og_type":"article","og_title":"Mijelofibroza - Humanitas.net","og_description":"Definicija Mijelofibroza je opasni poreme\u0107aj ko\u0161tane sr\u017ei. To je stanje kod koga dolazi do prekida normalne proizvodnje krvnih \u0107elija, a koje prouzrokuje stvaranje brojnih o\u017eiljaka na ko\u0161tanoj sr\u017ei \u0161to dalje rezultira anemijom, umorom, slabo\u0161\u0107u, a ponekad i uve\u0107anjem jetre i slezine. \u00a0Mijelofibroza je zaprvo jako redak oblik hroni\u010dne leukemije. Pripada grupi mijeloproliferativnih poreme\u0107aja. Neki slu\u010dajevi [&hellip;]","og_url":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/","og_site_name":"Humanitas.net","article_publisher":"https:\/\/www.facebook.com\/HumanitasInternational\/","article_modified_time":"2025-01-13T02:54:50+00:00","twitter_card":"summary_large_image","twitter_site":"@humanitasmilano","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/","url":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/","name":"Mijelofibroza - Humanitas.net","isPartOf":{"@id":"https:\/\/humanitas-net.humweb.webiz.team\/#website"},"datePublished":"2017-11-08T14:09:32+00:00","dateModified":"2025-01-13T02:54:50+00:00","breadcrumb":{"@id":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/#breadcrumb"},"inLanguage":"sr-RS","potentialAction":[{"@type":"ReadAction","target":["https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/diseases\/mijelofibroza\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/"},{"@type":"ListItem","position":2,"name":"Malattie","item":"https:\/\/humanitas-net.humweb.webiz.team\/malattie\/"},{"@type":"ListItem","position":3,"name":"Mijelofibroza"}]},{"@type":"WebSite","@id":"https:\/\/humanitas-net.humweb.webiz.team\/#website","url":"https:\/\/humanitas-net.humweb.webiz.team\/","name":"Humanitas.net","description":"Humanitas Hospital","publisher":{"@id":"https:\/\/humanitas-net.humweb.webiz.team\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/humanitas-net.humweb.webiz.team\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sr-RS"},{"@type":"Organization","@id":"https:\/\/humanitas-net.humweb.webiz.team\/#organization","name":"Humanitas","url":"https:\/\/humanitas-net.humweb.webiz.team\/","logo":{"@type":"ImageObject","inLanguage":"sr-RS","@id":"https:\/\/humanitas-net.humweb.webiz.team\/#\/schema\/logo\/image\/","url":"https:\/\/humanitas-net.humweb.webiz.team\/wp-content\/uploads\/2025\/01\/new-humanitas-logo-1.svg","contentUrl":"https:\/\/humanitas-net.humweb.webiz.team\/wp-content\/uploads\/2025\/01\/new-humanitas-logo-1.svg","width":1,"height":1,"caption":"Humanitas"},"image":{"@id":"https:\/\/humanitas-net.humweb.webiz.team\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/HumanitasInternational\/","https:\/\/x.com\/humanitasmilano"]}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/wp-json\/wp\/v2\/disease\/71212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/wp-json\/wp\/v2\/disease"}],"about":[{"href":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/wp-json\/wp\/v2\/types\/disease"}],"wp:attachment":[{"href":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/wp-json\/wp\/v2\/media?parent=71212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}